Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZYME with free AI briefings, catalyst countdowns, and dilution alerts.

ZYME · Zymeworks Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$100.5M Cash on Hand
10.8mo Cash Runway
12.9% Short Interest
$43.29 Analyst Target (14)
Follow ZYME by email Get an email when ZYME reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZYME, unsubscribe in one click. Privacy

📣 What ZYME Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zanidatamab (ZW25)
FDA approved Nov 2024 · Ziihera
Biliary Tract Neoplasms Phase 3 · NCT05615818 Recruiting
Tamoxifen Breast Cancer Phase 2 · NCT05035836 Recruiting
Anti-MSLN/Anti-CD3 Bispecific Antibody ZW171 Mesothelin-expressing Advanced Cancers Phase 1 · NCT06523803 Terminated
Anti-FRalpha Antibody-drug Conjugate ZW191 Advanced Solid Tumors Phase 1 · NCT06555744 Active not recruiting
Anti-GPC3 Antibody-drug Conjugate ZW251 Hepatocellular Carcinoma Phase 1 · NCT07164313 Recruiting
Zanidatamab Zovodotin (ZW49) HER2-expressing Cancers Phase 1 · NCT03821233 Completed

Also used in these trials (approved or third-party drugs, not ZYME's own candidates): Cisplatin, Trastuzumab, Niraparib, Neratinib, Ivosidenib, Gemcitabine Hydrochloride, Futibatinib, Encorafenib, Binimetinib, Letrozole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZYME holds $100.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $28M/quarter from operations, an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZYME files for a raise →

👥 Who Owns ZYME

Insiders 34.6% Institutions (295 holders) 65.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
EcoR1 Capital, LLC
Director, 10% owner
Insider 22,970,388 33.28% 2025-11-16
Rubric Capital Management LP Institution (13G, 5%+) 7,000,000 10.14% 2026-03-31
Blackrock Inc. Institution (13F) 4,212,745 6.10% 2026-09-30
Perceptive Advisors LLC Institution (13G, 5%+) 3,974,579 5.76% 2026-04-08
BVF Inc. Institution (13F) 3,464,142 5.02% 2026-09-30
Morgan Stanley Institution (13F) 3,236,915 4.69% 2026-09-30
BNP Paribas Asset Management Holding S.A Institution (13F) 1,781,031 2.58% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 1,558,998 2.26% 2026-09-30
Assenagon Asset Management S.A. Institution (13F) 1,508,069 2.18% 2026-09-30
Citadel Advisors Llc Institution (13F) 1,192,391 1.73% 2026-09-30
Gregory Austin Ciongoli
Director · +81,200 options
Insider 493,500 0.71% 2025-08-11
Kenneth Galbraith
Chair & CEO, Director · +582,000 options
Insider 226,842 0.33% 2026-01-12

Share count 69,030,691 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-13
filed 2026-11-16
Moore Paul Andrew
Option exercise (M) 25,000 $5.82 73,497
2026-11-13
filed 2026-11-16
Moore Paul Andrew
Sale (S) 7,367 $26.14 66,130
2026-11-13
filed 2026-11-16
Moore Paul Andrew
Sale (S) 7,374 $26.09 58,756
2026-11-13
filed 2026-11-16
Moore Paul Andrew
Sale (S) 25,000 $26.04 33,756
2026-11-13
filed 2026-11-16
Moore Paul Andrew
Option exercise (M) 25,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-08-25 Ziihera NDA +25.9% -4.5% —

Browse all historical PDUFA outcomes →

Get the full ZYME picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZYME and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.